Chase Therapeutics Corp — Form D
Chase Therapeutics Corp of WASHINGTON, DC, a company, filed a Form D exempt-offering notice with the SEC on 2018-08-28. The offering totals $4.0M, of which $4.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2018-08-28
- Form: D
- Accession: 0001723805-18-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.0M
- Amount sold: $4.0M
- Minimum investment: $1
- Investors: 3
- Date of first sale: 2018-08-21
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-320230
Issuer
- Name: Chase Therapeutics Corp
- CIK: 0001723805
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 1825 K STREET NW, WASHINGTON, DC, 20006
- Phone: 202-223-7002
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Thomas N Chase | Director | Washington, DC |
| Kathleen N Clarence-Smith | Director | Washington, DC |
| Karoly P Nikolich | Director | Washington, DC |
| John P Reher | Director | Washington, DC |
| Thomas N Chase | Executive Officer | Washington, DC |
| Richard P Dulik | Executive Officer | Washington, DC |
Other filings by this issuer (1)
More